Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STAT3 | P40763 | 1/20 | 0.37 |
| ▸ | STAT1 | P42224 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28676277 | 0.98 | STAT3 (0.36) | STAT3STAT1 | |
| SCHEMBL19490351 | 0.93 | GRIA1 (0.32) | STAT3STAT1 | |
| SCHEMBL6566436 | 0.90 | STAT3 (0.32) | STAT3STAT1 | |
| SCHEMBL461737 | 0.83 | STAT3 (0.37) | STAT3STAT1 | |
| SCHEMBL27728578 | 0.82 | STAT3 (0.36) | STAT3STAT1 | |
| SCHEMBL2752554 | 0.79 | STAT3 (0.36) | STAT3STAT1 | |
| Formic Acid SCHEMBL27490312 | 0.78 | STAT3 (0.36) | STAT3STAT1 | |
| SCHEMBL29267780 | 0.78 | STAT3 (0.36) | STAT3STAT1 | |
| SCHEMBL9866324 | 0.78 | STAT3 (0.49) | STAT3STAT1 | |
| SCHEMBL38329 | 0.78 | STAT3 (0.49) | STAT3STAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1353925-A2 | PROCESSES FOR LARGE SCALE PRODUCTION OF TETRAPYRROLES | Miravant Pharmaceuticals, Inc. (US) | 2003-10-22 | — | — | EP | claimed |
| WO-2002083686-A2 | PROCESSES FOR LARGE SCALE PRODUCTION OF TETRAPYRROLES | MIRAVANT PHARMACEUTICALS, INC. (US) | 2002-10-24 | — | — | WO | claimed |
| JP-7330773-A | — | — | None | — | — | JP | disclosed |
| JP-3284681-A | — | — | None | — | — | JP | disclosed |
| CN-119219645-B | Preparation method of substituted diphenyl porphyrin-2-formaldehyde | 湖南科技大学 | 2026-05-19 | — | — | CN | disclosed |
| CN-119219645-B | Preparation method of substituted diphenyl porphyrin-2-formaldehyde | 湖南科技大学 | 2026-05-19 | — | — | CN | disclosed |
| CN-119219645-A | Preparation method of substituted diphenyl porphyrin-2-formaldehyde | 湖南科技大学 | 2024-12-31 | — | — | CN | disclosed |
| CN-119219645-A | Preparation method of substituted diphenyl porphyrin-2-formaldehyde | 湖南科技大学 | 2024-12-31 | — | — | CN | disclosed |
| US-8952357-B2 | Cytochrome c552 color imaging element and method of manufacturing the same, cytochrome c552 photosensor and method of manufacturing the same, cytochrome c552 photoelectric transducer and method of manufacturing the same, and cytochrome c552 electronic device | SONY CORPORATION (JP) | 2015-02-10 | — | — | US | disclosed |
| CN-102318065-B | Color imaging element and method for manufacturing the same, optical sensor and method for manufacturing the same, photoelectric transducer and method for manufacturing the same, and electronic device | SONY CORP | 2013-11-27 | — | — | CN | disclosed |
| CN-103367642-A | Color imaging element and method of manufacturing the same, photosensor and method of manufacturing the same, and photoelectric transducer and method of manufacturing the same | SONY CORP | 2013-10-23 | — | — | CN | disclosed |
| US-20060183145-A1 | Use of reversible extension terminator in nucleic acid sequencing | PACIFIC BIOSCIENCES OF CALIFORNIA, INC. | 2006-08-17 | — | — | US | disclosed |
| WO-2006083751-A2 | USE OF REVERSIBLE EXTENSION TERMINATOR IN NUCLEIC ACID SEQUENCING | PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (US) | 2006-08-10 | — | — | WO | disclosed |
| WO-2006038823-A1 | BETA-SUBSTITUTED PORPHYRINS | MASSEY UNIVERSITY (NZ) | 2006-04-13 | — | — | WO | disclosed |
| US-20050277770-A1 | condensing a 5-acetaldipyrromethane with a dipyrromethane-1,9-dicarbinol to produce a porphyrin having an acetal group substituted thereon at the 5 position; and then hydrolyzing said porphyrin to produce said 5-formylporphyrin | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2005-12-15 | — | — | US | disclosed |
| US-20050277770-A1 | condensing a 5-acetaldipyrromethane with a dipyrromethane-1,9-dicarbinol to produce a porphyrin having an acetal group substituted thereon at the 5 position; and then hydrolyzing said porphyrin to produce said 5-formylporphyrin | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2005-12-15 | — | — | US | disclosed |
| EP-1353925-A2 | PROCESSES FOR LARGE SCALE PRODUCTION OF TETRAPYRROLES | Miravant Pharmaceuticals, Inc. (US) | 2003-10-22 | — | — | EP | disclosed |
| WO-2002083686-A2 | PROCESSES FOR LARGE SCALE PRODUCTION OF TETRAPYRROLES | MIRAVANT PHARMACEUTICALS, INC. (US) | 2002-10-24 | — | — | WO | disclosed |
| JP-H07330773-A | PORPHYRIN DERIVATIVE AND ITS USE | TOYO HATSUKA KOGYO KK | 1995-12-19 | — | — | JP | disclosed |
| JP-H03284681-A | PORPHYRIN DERIVATIVE | TOYO HATSUKA KOGYO KK | 1991-12-16 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050277770-A1 | condensing a 5-acetaldipyrromethane with a dipyrromethane-1,9-dicarbinol to produce a porphyrin having an acetal group substituted thereon at the 5 position; and then hydrolyzing said porphyrin to produce said 5-formylporphyrin | DHPS, NOTUM, DOHH | STAT3 4298/4885STAT1 4505/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.